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Background: Nonalcoholic steatohepatitis (NASH), the advanced stage of nonalcoholic fatty liver disease that is
characterized by both steatosis and severe injury in liver, still lacks efficient treatment. The traditional Chinese
formula Salvia–Nelumbinis naturalis (SNN) is effectively applied to improve the symptoms of nonalcoholic simple
fatty liver (NAFL) patients. Previous studies have confirmed that SNN could reduce the liver lipid deposition and
serum transaminases of NAFL experimental models. This study aims to determine whether SNN is effective for
murine NASH model and investigate the underlying pharmacological mechanisms.
Methods: C57BL/6 J mice were fed with methionine- and choline-deficient (MCD) diet for six weeks to induce NASH.
Simultaneously, SNN or saline was intragastrically administered daily to the mice in the SNN or model group,
respectively. A standard diet was given to the control mice. Serum biochemical indices and tumor necrosis factor-α were
measured. Liver histopathology was observed, and the contents of triglycerides and lipid peroxide malondialdehyde
(MDA) in liver homogenates were evaluated. The hepatic expression and/or activation of genes associated with
inflammation, apoptosis, and oxidative stress were determined by quantitative RT-PCR or Western blot analysis.
Results: The prominent liver steatosis displayed in the NASH model was prevented by SNN. The liver injury of NASH
mice was obviously manifested by the increased levels of serum transaminases and bilirubin, as well as the lobular
inflammation, elevated pro-inflammatory cytokines, and upregulated apoptosis in liver tissues. SNN administration
improved the aforementioned pathological changes. The increased hepatic levels of MDA and cytochrome P450
2E1 of the model confirmed the unregulated balance of oxidative stress. The hepatic expression of nuclear factor
erythroid 2-related factor 2 and its target genes decreased, whereas c-Jun N-terminal kinase activation in the
model mice increased. Treating the mice with SNN significantly improved oxidative stress-related harmful factors.
Conclusions: This study shows that SNN can protect the liver from severe steatosis and damage induced by MCD diet,
which suggests the potential use of SNN on the treatment of NASH patient. The results also indicate that improving the
hepatic antioxidant capability of the liver may contribute to the underlying hepatoprotective mechanism.
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Nonalcoholic fatty liver disease (NAFLD) is an increas-
ing prevalent health problem that ranges from simple
fatty infiltration of the liver parenchyma (nonalcoholic
simple fatty liver, NAFL) to steatosis with inflammation
and hepatocellular ballooning (nonalcoholic steatohe-
patitis, NASH) and ultimately cirrhosis [1]. Patients with
NAFL appear to have a nonprogressive course with
benign prognosis. However, approximately 10% to 30%
of NAFL patients develop NASH with more serious
form of liver damage, which may further progress to
cirrhosis in as many as 25% of the cases and suffer from
its complications, including portal hypertension, liver
failure and hepatocellular carcinoma [2].
NAFLD begins with an aberrant lipid accumulation in
the liver [3], followed by initial changes that induce the
liver to be sensitive to oxidative stress (OS) and pro-
inflammatory cytokines [4]. OS is an etiological factor
in many acute and chronic liver diseases and plays a
critical role in the progression of NAFL to NASH [5].
Sources of OS include elevated level of cytochrome P450
2E1 (CYP2E1), lipid peroxidation, and cytokine induction
[6,7]. CYP2E1 is an inducible enzyme hydroxylating
fatty acid that can initiate lipid peroxidation process
[8,9]. CYP2E1 is frequently induced in NASH, leading
to increased reactive oxygen species (ROS) that trigger
OS [8]. Considerable OS causes lipid peroxidation of
cell membrane and activation of hepatic stellate cell,
resulting in inflammation, apoptosis, and fibrogenesis
[10]. Increased OS can enhance the secretion of inflamma-
tory cytokines and hepatocyte apoptosis, which possess
pivotal roles in the pathogenesis of liver damage in NASH
[11-13]. Pro-inflammatory cytokines, such as tumor
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β),
which are involved in liver injury and repair, are also
considered as NASH indicators [14-17]. TNF-α plays
an important role throughout the progression of steatosis
to NASH [12]. The effects of TNF-α result in additional
lipid peroxidation of mitochondrial membranes, thereby
further enhancing OS in NASH [18]. Therefore, inhibiting
TNF-α can suppress liver injury in NASH [19].
Valuable therapeutic interventions against NASH
remain limited; hence, searching for a safe and effective
drug is relatively essential [20]. Salvia–Nelumbinis nat-
uralis (SNN) formula (initially called Jiang Zhi Granule)
is a compound prescription in traditional Chinese medi-
cine composed of five medicinal herbs, namely, Salviae
(Danshen in China), Nelumbinis (Heye in China), Herba
Gynostemmatis (Jiaogulan in China), Rhizoma Polygoni
Cuspidati ( Huzhang in China), and Herba Artemisiae
scopariae (Yinchen in China) [21,22]. This complex pre-
scription has been used to treat NAFL in clinical practice
in China, with significant effects of alleviating hepatic stea-
tosis with few side effects [23]. In 2008, SNN was grantedthe permission and certification by the Chinese SFDA
(No. 2008 L11181) to be used as drug for clinical trials.
SNN can improve the liver to spleen ratio (L/S ratio)
and decrease the body mass index of NAFL patients
[23]. Previous in vivo studies have also confirmed the
effect of SNN on NAFL and partially unraveled its
underlying mechanisms, including improving leptin and
insulin resistance, inhibiting transcription of liver X
receptor α (LXR-α)-mediated sterol regulatory element
binding protein-1c (SREBP-1c), and maturation of
SREBP-1c independent of LXR-α [24-27]. In vitro studies
have indicated that the components extracted from SNN
reduce lipid droplet deposition and increase the resistance
to damage of hepatocytes induced by free fatty acids
[21,28]. Taken together, our previous studies mainly
focused on the therapeutic function of SNN on simple
steatosis. Therefore, in the present study, we tried to
determine whether and how SNN is potentially effective
for NASH. For this objective, the NASH model of mouse
induced by methionine- and choline-deficient (MCD) diet
was used, of which the major pathological factors are
excess OS and failure of lipid transport from hepatocytes
[29]. SNN extract was administered to the NASH model
to observe the efficacy and to further investigate the
related molecular mechanism of the traditional formula.
Methods
Experimental animals
Male C57BL/6 J mice weighing 20 g to 25 g were pur-
chased from Shanghai SLAC Laboratory Animal Tech-
nology Company (License No. SCXK (HU) 2007–0005).
The animals were housed in a standard 12 h light/dark
cycle at 22 ± 2°C with 55 ± 10% humidity and had access
to food and water. The animal experiments were approved
by the Institutional Animal Care and Use Committee of
Shanghai University of Traditional Chinese Medicine. All
animal procedures were performed in accordance to the
guide for the care and use of laboratory animals [30].
Drug and chemicals
SNN was provided by the Department of Pharmacy of
Longhua Hospital, Shanghai, China. This herbal formula
was triturated and blended to powder. Subsequently, 20 mg
of the powder was extracted with 25 mL of water/methanol
(5:95, V/V) in an ultrasonic bath at 42 kHz frequency for
30 min. The chemical profile of SNN has already been
analyzed by ultra-performance liquid chromatography
[28]. SNN was stored at 4°C and diluted to the desired
concentrations in distilled water at the time of adminis-
tration. Hematoxylin–eosin (HE) solution was purchased
from Yixin Biological Technology, Inc. (Shanghai, China),
and Oil red O was from Sigma-Aldrich (St. Louis, MO,
USA). All reagents were at least of analytic grade and
applied according to manufacturer’s instructions.
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A total of 36 C57BL/6 J mice were adaptively fed for
7 days and were randomly allocated into the following
experimental groups (n = 12 per group) according to
their body weights: (1) the control mice given a standard
control diet, (2) the model mice fed with MCD diet, and
(3) mice fed with MCD diet together with oral garvage
of SNN (860 mg/kg body weight) once a day. The appli-
cation dose of SNN was calculated based on the standard
dose in clinical practice, previous in vivo experiments,
dose conversion among animals and human, and extract
yield [22,25,26,28]. The MCD and control diets were pur-
chased from Research Diets, Inc. (New Brunswick, NJ,
USA). At the end of the sixth week, all animals were fasted
overnight and sacrificed. The serum was separated for
further investigation. Mice livers were weighed and frozen
or fixed in 10% formalin.
Serum biochemical analysis
The alanine aminotransferase activity (ALT), aspartate
aminotransferase activity (AST), total bilirubin (TBIL),
total cholesterol (TC), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-c), and low-density lipo-
protein cholesterol (LDL-c) were determined to assess
liver function using commercially available kits (Jiancheng
Institute of Bio Engineering, Inc., Nanjing, China) ac-
cording to the manufacturer’s instructions. The serum
concentration of TNF-α was measured by a Bio-Plex
assay kit (Bio-Rad, Hercules, USA) with the Bio-Plex
200 system (Bio-Rad).
Histological examination
The liver sections were stained with HE according to the
standard methods. In brief, the fresh liver tissue samples
were fixed in 10% formalin and embedded in paraffin.
The samples were cross-cut into slices of 4 μm to 5 μm
and stained with HE staining solution. Finally, the
stained sections were observed and photographed under
a light microscope (with 200× magnification). All HE
stained sections (n = 12) were evaluated in a blinded
manner by two pathologists for NAFLD activity score
(NAS) including the components of steatosis, inflamma-
tion and hepatocyte ballooning. The scoring system was
as follows: steatosis grade (0–3; 0: <5%, 1: 5%–33%, 2:
33%–66%, and 3: >66%), lobular inflammation (0–3; 0:
no foci, 1: few foci/200×, 2: many foci/200×, and 3: >4
foci/200× scope), and balooning (0–2; 0: no foci, 1: <2
foci/200×, and 2: 2–4 foci/200× [31].
Oil Red O staining
For Oil Red O staining, a stock solution of Oil Red O
(0.5 g/100 mL) in isopropanol was prepared, and pro-
tected from light. After being fixed with 10% paraformal-
dehyde for 30 min, the frozen liver sections with 10 μmthickness were stained with Oil Red O for 60 min. Non-
specific staining was removed with 70% ethanol. The
sections were counterstained with hematoxylin diluted
at 1:10 and mounted with 80% glycerol. The stained
sections were visualized and photographed under a
microscope (Olympus IX71, Tokyo, Japan).
Evaluation of lipid content in liver tissues
Exactly 3 ml of Ethanol–acetone (1:1) was added to the
hepatic tissues (200 mg), which was then homogenized
in an ice bath and mixed thoroughly at 4°C overnight.
After 24 h, the liver tissues were centrifuged at
3000 rpm and 4°C for 20 min. Subsequently, the super-
natant was transferred to a new tube, and TG was mea-
sured based on the instructions on TG assay kit (Jiancheng
Institute of Bio Engineering, Inc.) using the colorimetric
method.
Measurement of MDA in liver tissues
The contents of malondialdehyde (MDA) in the liver
tissues were determined through thiobarbutaric acid
(TBA) method using a MDA testing kit (Beyotime Institute
of Biotechnology, shanghai, China). Briefly, the liver tissues
(200 mg) were homogenized in 0.15 M KCl solution. The
homogenate and 10% trichloroacetic acid were mixed (1:1)
and centrifuged. The supernatant was suspended into
TBA. After placing in a water bath for 15 min, the samples
were centrifuged at 1000 g for 15 min. The optical density
of the supernatants was measured at 532 nm with a BioTek
SynergyH4 enzyme-labeled instrument (USA).
Quantitative reverse transcription polymerase chain
reaction (RT-PCR)
The changes of different genes in the liver tissues of
MCD mice were validated by conducting quantitative
RT-PCR. The total RNA was converted to cDNA by
using reverse transcription kits (Promega, Madison, WI,
USA). All primers were synthesized by Shanghai Shine
Gene Company. The sequences of the primers used in
this study are indicated in Table 1. Quantitative RT-PCR
was then performed using a SYBR Green PCR Master Mix
kit (Applied Biosystems, Carlsbad, CA, USA) according to
the manufacturer’s protocol. Amplification of β-actin was
performed in parallel as a relatively invariant internal
reference. The 2−ΔΔCt method was applied for data analysis.
Western blot
Protein concentration was determined using a BCA pro-
tein assay kit (CoWin Bioscience, Beijing, China). The
protein sample was resolved by 10% denaturing sodium
dodecyl sulfate polyacrylamide gel electrophoresis and was
blotted onto Immobilon-P PVDF membranes (Millipore,
Billerica, MA, USA). After being blocked by 5% milk, the
membrane was incubated with primary antibodies at 4°C
Table 1 The primer sequences for quantitative RT- PCR
used in this study
Gene Primer sequence
β-actin Forward : 5′-GAGACCTTCAACACCCCAGC-3′
Reverse : 5′-ATGTCACGCACGATTTCCC-3′
TNF-α Forward : 5′-CCCTCCAGAAAAGACACCATG-3′
Reverse : 5′-CACCCCGAAGTTCAGTAGACAG-3′
IL-1β Forward : 5′-TCGTGCTGTCGGACCCAT-3′
Reverse : 5′-GGCTTGTGCTCTGCTTGTGA-3′
CYP2E1 Forward : 5′-AGGCTGTCAAGGAGGTGCTAC-3′
Reverse : 5′-GTTTCCCCATTCCCCAGTC-3′
Nrf2 Forward : 5′-TCTTCCATTTACGGAGACCCA-3′
Reverse : 5′-GATTCACGCATAGGAGCACTG-3′
Nqo1 Forward : 5′-TCAACTGGTTTACAGCATTGGC-3′
Reverse : 5′-GCTTGGAGCAAAATAGAGTGGG-3′
Gstp1 Forward : 5′-ACCCTGCTGTCCCAGAACC-3′
Reverse : 5′-GCGAGCCACATAGGCAGAG-3′
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kinase (JNK), Phospho-JNK, activated Caspase-3, Bcl-
2-associated X (Bax) protein, and Bcl-2 were purchased
from Cell Signaling Technology (Danvers, MA, USA). The
antibody against CYP2E1 was obtained from Abcam
(Cambridge, MA, USA), and β-actin was obtained from
Huaan Biological Technology (Hangzhou, China). Subse-
quently, the membrane was incubated in a horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse
secondary antibody from Thermo Scientific (Rockford,
IL, USA) for 1 h. The signal was visualized by enhanced
chemiluminescence HRP substrate (Millipore, Billerica,
MA, USA) and acquired by GBOX Chemi XT4 System
(Syngene, Cambridge, UK). GeneTools software (Syngene)
was used for quantification.
Statistical analysis
The data were expressed as mean ± standard deviation.
Statistical analyses were carried out using one-way
ANOVA, followed by Tukey’s post-hoc test to assess the
differences between the two groups. The data from qPCR,
Western blot and pathological scores were compared using
Kruskal–Wallis ANOVA test followed by Dunn’s multiple
comparison test. SPSS 18.0 was used for all statistical
analyses. P <0.05 was considered statistically significant.
Results
SNN reversed the changes in body and liver weights and
serum lipid of the NASH model
The body and liver weights of mice were measured at the
end of the experiment. In contrast to those of the control
group, the body weight, liver weight, and liver–body
weight ratio remarkably decreased in the NASH model(P <0.001). These parameters significantly improved in
mice treated with SNN (P <0.001) (Figure 1A).
Statistically significant differences were also observed
in the blood lipid content. The serum levels of TG, TC,
HDL-c, and LDL-c decreased in the model group (P <0.001),
which were prevented by SNN intervention to a certain
extent, particularly the levels of TC, HDL-c (P <0.01),
and LDL-c (P <0.05) (Figure 1B).
SNN ameliorated hepatosteatosis induced by MCD diet
The MCD-induced NASH model was established after the
mice were fed with MCD diet for six weeks. Figure 2A
shows that the liver sections of the model mice stained
with HE and Oil Red O displayed abundant accumulation
of fat droplets in hepatocytes, together with scattered
inflammatory cell infiltration and hepatocellular balloon-
ing degeneration, which were all improved in mice treated
with SNN. The steatosis grade of the liver tissue was
higher in the model group than in the control group
(P <0.001) but was significantly downregulated in the
SNN group (P <0.05) (Table 2). The increased liver TG
content (P <0.001), which was another proof of lipid
deposition in the livers of model mice, was consistently
reduced by SNN (P <0.05) (Figure 2B).
SNN attenuated liver injury induced by MCD diet
Liver damage was exhibited by the elevated serum values
of ALT (P <0.01), AST (P <0.01), and TBIL (P <0.001) in
the model group compared with the control group. SNN
treatment prevented the changes to a certain extent
(Figure 3A). Inflammatory cytokines were implicated in
the pathogenesis of NASH. The MCD diet increased the
serum level of TNF-α (P <0.001) and hepatic TNF-α
expression (P <0.05) in the model group, which was
blocked by SNN (Figure 3B, C). The direct evidence of
liver injury was determined by lobular inflammation and
hepatocyte death in liver sections. The lobular inflam-
matory grade (P <0.001), ballooning grade (P <0.01) and
the aggregate NAS (P <0.001) were higher in the model
mice but was downregulated in the SNN group (Table 2).
The increased level of active caspase-3 (P <0.001) indi-
cated more apoptosis of the hepatocytes in MCD diet-
fed mice than in control mice. This phenomenon was
attenuated by SNN intervention (P <0.01). Compared
with that in the controlled mice, the anti-apoptosis
molecule Bcl-2 expression was reduced (P <0.05) in the
model mice but was upregulated in the SNN group
(P <0.05). The pro-apoptosis molecule Bax exhibited
the converse changing tendency (Figure 3D).
SNN regulated hepatic oxidative stress in MCD diet-induced
NASH
This study also found that SNN could improve the state
of OS. The levels of lipid peroxidation (MDA) were
Figure 1 Changes in body and liver weight and serum lipid of mice. (A) Body weight, liver weight, and liver-body weight ratio (n = 12 per
group). (B) Serum TG, TC, HDL-c, and LDL-c (n = 8 per group). Data are expressed as mean ± SD, ***P< 0.001 vs. control; ###P< 0.001, ##P< 0.01 vs. model.
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with those in the control (P <0.05) but were decreased
by SNN treatment (P <0.05) (Figure 4A). The mRNA
level of CYP2E1 was not remarkably different among
the groups, but its protein level was increased in the
model mice and was downregulated by SNN (P <0.05)Figure 2 Liver histopathology and triglyceride content of mice. (A) He
mice from each group; CV indicates lobular central vein; the original mag
expressed per gram of tissue. Data are expressed as mean ± SD, n = 10 pe(Figure 4B, C). After the sixth week, the levels of
nuclear factor erythroid 2-related factor 2 (Nrf2) and
its target genes, Nqo1 and Gstp1, decreased in the
MCD diet-induced NASH model (P <0.05 vs. control)
but increased in mice administered with SNN (P <0.05
vs. model) (Figure 4B). JNK is reported as the bridgematoxylin–eosin or Oil Red O staining of liver sections from representative
nification is 200×. (B) Liver triglycerides were measured. Results are
r group, ***P < 0.001 vs. control; #P < 0.05 vs. model.
Table 2 Liver histology evaluated by NAFLD Activity
score
Group Control Model SNN
Steatosis grade 0 ± 0 2.6 ± 0.52*** 0.75 ± 0.71#
Lobular inflammatory grade 0 ± 0 2.0 ± 0.76*** 0. 5 ± 0.53#
Hepatocellular balooning 0 ± 0 1.4 ± 0.92** 0. 6 ± 0.52
NAS 0 ± 0 4.8 ± 1.90*** 1.9 ± 0.79#
Data are expressed as mean ± SD, n = 12 per group, ***P < 0.001, **P < 0.01 vs.
control; #P < 0.05 vs. model.
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in JNK expression was observed among various groups.
However, the level of its active form (p-JNK) increased
more than fourfold (P <0.01) in the model mice and was
reduced in the SNN group (P <0.05) (Figure 4C).
Discussion
NASH progression is mediated by an inflammatory
process in the liver with concomitant tissue damage.Figure 3 Liver injury-related parameters of mice. (A) Serum ALT, AST a
measured by Bio-Plex 200 system with Luminex system after labeling with
expression of the liver pro-inflammatory cytokines TNF-α and IL-1β was eva
to β-actin expression (n = 4 per group). (D) The expression of apoptosis-rela
immunoblot analysis of livers from four mice per group. β-actin was determin
**P < 0.01, *P < 0.05 vs. control; ###P < 0.001, ##P < 0.01, #P < 0.05 vs. model.MCD diet-induced model is considered convenient for
examining the role of OS and inflammation in the pro-
gression of NAFLD [33-35]. Choline and methionine are
essential components for very-low-density lipoprotein
(VLDL) and lipid oxidation. The deficiency of these
components can reduce lipid oxidation and lipid trans-
port outside of the hepatocytes, resulting in lipid accu-
mulation in the liver. Choline and methionine deficiency
also causes loss of active methyl which is important for
glutathione cycle, leading to decreased antioxidants and
promotion of OS [36,37]. The mice fed with MCD diet
lost weight because of reduced caloric intake, which is in
contrast to humans with NASH who are mostly obese.
Thus, differences exist between MCD dietary mouse
model and human NASH [37]. However, the MCD
NASH model is one of the best established and com-
monly used dietary models for studying the evolution of
inflammation and OS changes associated with NASH
[38-40]. Liver injury and OS rapidly occur in MCD diet-nd TBIL were measured (n = 8 per group). (B) Serum TNF-α level was
specific Luminex magnetic beads (n = 8 per group). (C) Hepatic mRNA
luated by quantitative real-time PCR analysis. Results were normalized
ted genes including active caspase-3, BAX, and Bcl-2 was evaluated by
ed as the loading control. Data are expressed as mean ± SD, ***P < 0.001,
Figure 4 Parameters of oxidative stress of mice. (A) The MDA content of liver was measured. Results are expressed per gram of liver protein
extract (n = 8 per group). (B) The hepatic mRNA expression of liver oxidant stress related genes including CYP2E1, Nrf2, Gstp1 and Nqo1 was
evaluated by quantitative real-time PCR analysis. Results were normalized to β-actin expression (n = 4 per group). (C) The expression of CYP2E1,
JNK and phospho-JNK was evaluated by immunoblot analysis of livers from four mice per group. β-actin was determined as the loading control.
Data are expressed as mean ± SD, ***P < 0.001, **P < 0.01, *P < 0.05 vs. control; #P < 0.05 vs. model.
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particular, severe pericentral steatosis may develop in
MCD diet-fed model after one week to two weeks;
necro-inflammation may occur after two weeks; progres-
sive pericellular and pericentral fibrosis may appear after
eight weeks; and markedly enhanced OS can be observed
from three weeks of MCD diet. Moreover, the liver injury
induced by MCD diet is similar to human NASH
[33,36,37]. In this study, MCD diet was used to feed
C57BL/6 J mice for six weeks. Compared with the mice
fed with control diet, hepatic steatosis appeared in the
liver tissue accompanied with hepatocellular ballooning
and scattered inflammatory cell infiltration, and trans-
aminase activities were significantly increased in the
MCD diet-fed mice, which indicate the establishment of
the NASH model.
This study demonstrated the strong effect of SNN
on preventing NASH development by simultaneously
administering MCD diet to mice. The mice fed with
MCD diet and administrated with SNN for six weeks
exhibited only mild lipid deposition in their livers,
instead of the prevalent hepatic steatosis, inflammation
and hepatocellular ballooning degeneration that occurred
in the NASH model without intervention. Consistently,
the hepatocellular injury indicated by the increased serum
levels of ALT, AST, bilirubin, and TNF-α and cell apop-
tosis in the model mice were evidently alleviated in the
mice of the SNN group. Compared with our previous
studies [22,25-27], the current study elucidated that SNNnot only ameliorated steatosis but also improved the more
serious liver injury in NASH. In addition, SNN blocked
the excessive loss of body and liver weights and decreased
the circulating lipid, which occurred in the NASH models.
This function is similar to preventing a body from
progressing into an unhealthy status.
Our previous studies identified insulin resistance,
leptin resistance, and upregulated free fatty acid (FFA)
synthesis as parts of the mechanisms involved in the
effect of SNN [24-27]. The model mice in the present
study showed lower serum levels of insulin and leptin, as
well as hepatic FFA synthetases, such as SREBP-1c and
stearol-CoA desaturase 1, than those of the control mice
(data not shown). By contrast, obviously increased levels
of MDA and CYP2E1 were observed in the livers of the
NASH mice induced by MCD diet, as reported in previ-
ous studies [34,40]. Thus, the present study further
focused on whether SNN could improve NASH through
regulating OS.
OS is a disturbance between the pro-oxidant/antioxi-
dant balance in favor of the former [41]. As an etiological
factor in NASH [42], OS can initiate hepatocellular injury
and secondary recruitment of inflammation [5,8]. Under-
standing the pathophysiological mechanisms of OS helps
in the development of NASH treatment [43]. MDA is a
lipid oxidant that is widely used as a marker of lipid oxida-
tion. MDA increased in 90% of NASH patients, illustrating
the increase of OS [42,44,45]. Generation of lipid perox-
ides results in subsequent damage to hepatic membranes,
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marker of OS. CYP2E1 can oxidize a variety of small
molecule substrate. Superoxide anion, a byproduct of the
CYP2E1-mediated metabolism, is a very potent ROS,
which may serve as part of the second hit to advance the
severity of NAFLD to NASH [46,47]. The results of this
study showed increased CYP2E1 and MDA in the hepatic
tissue of model mice, indicating the enhancement of OS.
Nrf2 serves as a master regulator of a cellular defense
system against OS. Upon exposure to ROS, Nrf2 dissoci-
ates and translocates into the nucleus, in which it binds
to cis-acting antioxidant-responsive elements (ARE) and
promotes the transcription of cytoprotective genes, such as
NAD(P)H-quinone oxidoreductase (Nqo) and glutathione-
S-transferase (Gst) [48]. Increased expression of Nrf2 has
been reported in mice fed with MCD diet for two weeks as
an adaptive response to elevated ROS [49]. However, in the
present study, low levels of Nrf2 and its targeted genes,
Nqo1 and Gstp1, were observed in the model mice. This
result may be attributed to the exhaustion of compensatory
mechanism for excess ROS after the mice were fed with
MCD diet for six weeks. Previous study has found that
livers of Nrf2 (−/−) mice on the MCD diet suffered more
OS than their wild-type counterparts did [50]. The
consequences of OS include lipid peroxidation in cell
membranes, stellate cell activation in the liver leading
to liver fibrosis, chronic inflammation, and apoptosis
[35,43]. Moreover, ROS overproduction can promote
hepatic insulin resistance, which further aggravates
fatty liver [43]. Increased CYP2E1 activity correlates
with the degree of steatosis and level of the inflamma-
tory cytokines (e.g., TNF-α) involved in the pathology
of NASH [6]. Thus, in the murine MCD diet-induced
NASH model, hepatic injury develops as the decreased
hepatocellular antioxidant defenses is overwhelmed by
OS [43]. The mice of the SNN group demonstrated
lower levels of MDA and CYP2E1 than the mice fed
with MCD diet but exhibited more expressions of Nrf2,
Nqo1, and Gstp1. Thus, administratering SNN helped
reverse the OS imbalance. This finding may be attributed
to the integrated function of the natural components
contained in SNN, such as protopanaxadiol, berberine,
and resveratrol. These components are antioxidants
that could directly scavenge free radicals or regulate the
correlated factors [21,51-53].
Apoptosis is a common mechanism of liver injury.
The hepatocyte apoptosis assessed by terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL) of
liver biopsies and active caspases-3 and −7 significantly
increases in patients with NASH and correlates with
disease severity [54]. The mitogen-activated protein kinase
JNK signaling pathway contributes to stress-induced apop-
tosis. Previous studies demonstrated that sustained JNK
activation occurs with the development of steatohepatitis,which can be activated by overexpression of CYP2E1 in
NASH. The JNK pathway may be a link between OS and
apoptosis [32,55]. OS-associated JNK-mediated apoptosis
requires the activation of the transcription factor c-Jun or
induces apoptosis in a transcription-independent process
by activating proapoptotic members of the Bcl-2 family,
including Bim and Bax, or inactivating Bcl-2 and Bcl-xL
[56,57]. Consistently, this study observed that the acti-
vation of caspase-3 and JNK increased in the MCD
diet-induced NASH model, together with low expression
of Bcl-2. Such finding implies that JNK may mediate apop-
tosis by regulating Bcl-2. SNN treatment significantly
increased the level of activated caspase-3 and JNK and
downregulated Bcl-2, suggesting the function of SNN in
the regulation of the pathway of OS–JNK apoptosis.
Conclusions
By administering SNN in the MCD diet-induced murine
model, this study demonstrates that SNN has a beneficial
effect on inhibiting hepatic steatosis and improving liver
injury, including inflammation and hepatocyte apoptosis
in NASH. The results of this study suggest the potential
application of SNN in treating NAFLD with serious form
of liver injury. However, these findings still require further
validation by conducting clinical trials. SNN is a complex
herbal medicine that may possess multiple pharmaceutical
targets; however, in this study, the effect of regulating
OS as well as subsequent anti-apoptosis and anti-
inflammation functions were prominently observed to
attenuate liver injury. Such functions contribute to
explain the mechanism of SNN in modulating the
pathophysiology of NASH. Furthermore, since OS and
inflammation are also the major mechanism of alcoholic
fatty liver disease [46,58,59], SNN might also have
potential for the treatment of this common liver disease.
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